Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Pazopanib synovial sarcoma not applicable detail...
Unknown unknown Anlotinib synovial sarcoma not applicable detail...
FGFR1 amp PD173074 synovial sarcoma sensitive detail...
FGFR1 amp AZD4547 synovial sarcoma sensitive detail...
FGFR1 amp BGJ398 synovial sarcoma sensitive detail...
FGFR1 positive PD173074 synovial sarcoma decreased response detail...
FGFR1 positive AZD4547 synovial sarcoma decreased response detail...
FGFR1 positive BGJ398 synovial sarcoma decreased response detail...
Unknown unknown Regorafenib synovial sarcoma not applicable detail...
Unknown unknown Pembrolizumab synovial sarcoma not applicable detail...
Unknown unknown SU6656 synovial sarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed
NCT01343043 Phase Ib/II NY-ESO-1-c259T A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma (NY-ESO-1) Recruiting
NCT01446809 Phase I Doxorubicin + Ifosfamide Pazopanib + Doxorubicin + Ifosfamide Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Unknown status
NCT02210104 Phase I Ipilimumab Cyclophosphamide Adoptive Therapy Using Antigen-Specific CD4 T-Cells Withdrawn
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Active, not recruiting
NCT02584309 Phase II dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting
NCT02601937 Phase I Tazemetostat A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Recruiting
NCT02601950 Phase II Tazemetostat A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting
NCT02609984 Phase II Atezolizumab G305 + ID-LV305 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Active, not recruiting
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting
NCT02978859 Phase II MGCD516 MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas Recruiting
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03450122 Phase I Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305 Aldesleukin + Cyclophosphamide Aldesleukin + Cyclophosphamide + ID-LV305 Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma Recruiting
NCT03520959 Phase III CMB305 Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma Active, not recruiting
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Not yet recruiting